Sample Reports
See Exactly What You'll Get
Browse sample reports generated from fictional data. Each report follows the same structure you'll receive with your personal genetic results.
Explore Our Sample Reports
Three clinically-grounded reports, each covering a different aspect of your genetic health. Preview any of them below.
Medication Safety
Medication Safety Report
150+ drug-gene interactions across 13 pharmacogenes with risk snapshot, medication checklist, and clinician summary.
$49 one-time
Nutrition
Nutrition & Methylation Report
MTHFR, folate, B12, and vitamin D variants with priority dashboard and food-first action plan.
View sample →Psychiatric
Psychiatric Medication Report
Antidepressants, ADHD meds, and mood stabilizers mapped to CYP2D6 + CYP2C19 with condition-based grouping.
View sample →Medication Safety Report — Full Sample
Medication Safety Report
Pharmacogenomic Analysis — DecodeMyBio
Report Date: February 12, 2026
Report ID: DMB-2026-SAMPLE
Risk Snapshot
Moderate Risk
Overall Medication Genetic Risk
0
Significant
3
Moderate
13
Genes Tested
Next step: Share this report with your prescriber before starting or changing any of the medications listed below.
90-Second Summary
Genes with findings
3 of 13
CYP2C19, CYP2D6, SLCO1B1
Medications affected
12+
Including clopidogrel, codeine, simvastatin
Risk level
Moderate
No significant findings; 3 moderate
Your results show altered enzyme activity in 3 pharmacogenes. This means your body may process certain medications differently than expected. None of your findings are classified as significant risk, but each one may warrant a dosing adjustment or alternative medication.
When This Report Matters
- ●You are prescribed clopidogrel (Plavix) after a cardiac stent — your CYP2C19 result means the standard dose may be less effective.
- ●Your doctor prescribes codeine for pain relief — your CYP2D6 result suggests reduced conversion to the active form.
- ●You start simvastatin (Zocor) for cholesterol — your SLCO1B1 result indicates higher risk of muscle-related side effects at standard doses.
Clinician Pocket Summary
One-Page Clinical Reference
| Gene | Diplotype | Phenotype | Activity | Key Medications | Suggested Action |
|---|---|---|---|---|---|
| CYP2C19 | *1/*2 | Intermediate Metabolizer | 1.0 | Clopidogrel, escitalopram, sertraline | Consider alternative antiplatelet; adjust SSRI if needed |
| CYP2D6 | *1/*4 | Intermediate Metabolizer | 1.0 | Codeine, tramadol, amitriptyline | Avoid codeine; consider alternative analgesic |
| SLCO1B1 | *1A/*5 | Decreased Function | N/A | Simvastatin, atorvastatin | Use lower simvastatin dose or alternative statin |
Detailed Gene Findings
CYP2C19
*1/*2 — Intermediate Metabolizer
You carry one reduced-function CYP2C19 allele. This enzyme activates clopidogrel and metabolizes several SSRIs. With intermediate metabolizer status, you may have reduced activation of clopidogrel and altered SSRI levels.
Affected Medications
Clinical Recommendation
CPIC recommends considering an alternative antiplatelet agent (e.g., prasugrel or ticagrelor) for CYP2C19 intermediate metabolizers requiring antiplatelet therapy. For SSRIs, consider dose adjustment or therapeutic drug monitoring.
CYP2D6
*1/*4 — Intermediate Metabolizer
You carry one non-functional CYP2D6 allele. CYP2D6 metabolizes approximately 25% of all prescribed drugs. As an intermediate metabolizer, you have reduced enzyme activity, which can affect both prodrug activation and drug clearance.
Affected Medications
Clinical Recommendation
CPIC recommends avoiding codeine in intermediate metabolizers due to reduced conversion to morphine and unpredictable analgesic response. Consider alternative analgesics. For tricyclic antidepressants, consider a 25% dose reduction.
SLCO1B1
*1A/*5 — Decreased Function
You carry one reduced-function SLCO1B1 allele (rs4149056 TC). SLCO1B1 encodes a transporter that moves statins into liver cells. Decreased function leads to higher statin blood levels, increasing the risk of myopathy (muscle pain and weakness).
Affected Medications
Clinical Recommendation
CPIC recommends prescribing a lower dose of simvastatin (max 20 mg/day) or considering an alternative statin such as pravastatin or rosuvastatin, which are less affected by SLCO1B1 variation.
Other Genes Tested
These genes were analyzed and returned normal or expected results. No dosing changes are indicated based on current CPIC guidelines.
| Gene | Diplotype | Phenotype |
|---|---|---|
| CYP2C9 | *1/*1 | Normal Metabolizer |
| CYP3A5 | *3/*3 | Poor Metabolizer |
| CYP1A2 | *1F/*1F | Normal/High Inducer |
| CYP3A4 | *1/*1 | Normal Metabolizer |
| CYP2B6 | *1/*1 | Normal Metabolizer |
| DPYD | *1/*1 | Normal Metabolizer |
| TPMT | *1/*1 | Normal Metabolizer |
| NUDT15 | *1/*1 | Normal Metabolizer |
| UGT1A1 | *1/*1 | Normal Metabolizer |
| VKORC1 | -1639 G/G | Normal Sensitivity |
Medication Checklist
Medications checked against your genetic profile. Actionable items have a gene-drug interaction that may affect dosing or drug choice.
Clopidogrel (Plavix)
Escitalopram (Lexapro)
Citalopram (Celexa)
Sertraline (Zoloft)
Codeine (Tylenol #3)
Tramadol (Ultram)
Amitriptyline (Elavil)
Simvastatin (Zocor)
Atorvastatin (Lipitor)
Warfarin (Coumadin)
Omeprazole (Prilosec)
Ibuprofen (Advil, Motrin)
Severe Drug Reaction Risk (HLA-B)
Screening for HLA-B variants linked to severe drug hypersensitivity reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). Based on tag SNP proxies, not clinical HLA typing.
Affected medication: abacavir (Ziagen)
No HLA-B*57:01 risk allele was detected via tag SNP screening. This suggests a lower risk of abacavir hypersensitivity. This result is based on a tag SNP proxy and does not replace clinical HLA typing.
Affected medication: carbamazepine (Tegretol)
No HLA-B*15:02 risk allele was detected via tag SNP screening. This suggests a lower risk of carbamazepine-induced SJS/TEN. This result is based on a tag SNP proxy and does not replace clinical HLA typing.
Affected medication: allopurinol (Zyloprim)
No HLA-B*58:01 risk allele was detected via tag SNP screening. This suggests a lower risk of allopurinol hypersensitivity. This result is based on a tag SNP proxy and does not replace clinical HLA typing.
Limitations
- •Consumer genotyping arrays test a subset of known pharmacogenomic variants. Rare or novel alleles may not be detected.
- •Structural variants (e.g., CYP2D6 gene deletions or duplications) cannot be reliably determined from array data.
- •This report does not account for phenoconversion — when concomitant medications inhibit or induce enzyme activity, effectively changing your metabolizer status.
- •Allele frequency databases may underrepresent certain populations, potentially affecting phenotype assignment accuracy.
- •Drug response depends on multiple factors beyond genetics, including age, weight, kidney/liver function, diet, and other medications.
Glossary
- Diplotype
- The combination of two alleles (one from each parent) for a specific gene. For example, CYP2C19 *1/*2 means you inherited a *1 allele from one parent and a *2 allele from the other.
- Phenotype
- The predicted functional status of an enzyme based on your diplotype. Common phenotypes include Normal Metabolizer, Intermediate Metabolizer, and Poor Metabolizer.
- CPIC Level A
- The highest level of clinical evidence for a drug-gene interaction, as classified by the Clinical Pharmacogenetics Implementation Consortium. Level A means genetic information should be used to change prescribing of the affected drug.
This is a sample report generated with fictional data for demonstration purposes. Your actual report will reflect your personal genetic results.
What's Inside Your Report
Every Medication Safety Report includes these sections, covering genes like CYP2C19 and CYP2D6, and medications like clopidogrel
Risk Snapshot
Your overall medication genetic risk — High, Moderate, or Low — with a clear next step on the first page.
90-Second Summary
Top findings in plain language with affected medications and what to discuss with your provider.
Clinician Pocket Summary
A one-page clinical reference your doctor or pharmacist can review in under 60 seconds.
Detailed Gene Findings
Full analysis of each gene with your diplotype, phenotype, affected drugs, and CPIC-backed recommendations.
Complete Gene Panel
All 13 pharmacogenes tested with results — including the ones that came back normal.
Severe Drug Reaction Risk (HLA-B)
Screening for HLA-B variants linked to life-threatening drug reactions — abacavir, carbamazepine, and allopurinol.
Medication Checklist
Every medication checked against your genetics, with brand names you recognize and actionable/normal status.
Limitations & Glossary
Transparent disclosure of what this report can and cannot tell you, plus definitions of key terms.
Built on CPIC Guidelines
Every finding in this report cites evidence from the Clinical Pharmacogenetics Implementation Consortium (CPIC) — the same guidelines used by hospitals and pharmacies worldwide. Only Level A (strong) and Level B (moderate) evidence is included.
For educational and informational purposes only. Not a substitute for clinical pharmacogenomic testing or medical advice. See our limitations page for details.
Ready to Unlock Your DNA Reports?
Upload your 23andMe or AncestryDNA raw data file and get personalized reports on medication safety, nutrition, and psychiatric medications.